Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Ureteral Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1Renal Insufficiency 1Recurrence 1Prostatic Neoplasms 1Penile Neoplasms 1Neoplasms 1Kidney Neoplasms 1Carcinoma, Small Cell 1Carcinoma 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × vinflunine × Clear all
NCT00450515 2016-12-06

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Withdrawn
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00284180 2013-08-09

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

SCRI Development Innovations, LLC

Phase 2 Completed
32 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡